Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues

Note: EPS may not be comparable

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.23), $0.12 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $5.28 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• AeroVironment (AVAV) Tops Q4 EPS by 36c
• Trump discloses over $1.4 billion in crypto income in 2025 filing